Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: Ten-year outcome Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Urinary Bladder Neoplasms

abstract

  • The majority of patients with invasive bladder tumors who achieve T0 status after neoadjuvant MVAC chemotherapy preserve their bladders for up to 10 years with bladder-sparing surgery. The bladder remains at risk for new invasive tumors. Cystectomy salvages the majority, but not all, of relapsing patients.

publication date

  • April 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9552029

Additional Document Info

start page

  • 1298

end page

  • 301

volume

  • 16

number

  • 4